Baxter (NYSE:BAX) announced today that study findings supported stroke volume and cardiac monitoring for predicting patient outcomes.
The Baxter-sponsored study found that monitoring stroke volume and cardiac output trends for patients with critical conditions may offer vital insight into cardiac function and aid in predicting patient outcomes, including mortality.
Deerfield, Illinois-based Baxter’s study findings were presented in an abstract titled “Stroke Volume Change Predicts Patient Outcome” at the Society of Critical Care Medicine (SCCM) Critical Care Congress taking place April 18-21, 2022, according to a news release.
The study evaluated trends in stroke volume and cardiac output over time as they relate to outcomes for 127 critically ill patients. The patients in the intensive care unit received hemodynamic monitoring with the Baxter Starling fluid management monitoring system.
Among the patient population, 64% had sepsis and 15% had COVID-19. Study investigators found that patients exhibiting an overall improvement in stroke volume showed a decrease in mortality (14.9) compared to those who did not improve overall stroke volume (35%).
The findings also indicated that closely monitoring cardiac function may be important in preventing clinically relevant changes in patient outcome, Baxter said in the release.
“These findings reinforce the importance of using non-invasive patient monitoring technology to deliver quick and precise fluid management data that can help clinicians make more informed, personalized treatment decisions and help enhance outcomes for critically ill patients,” Baxter VP of Meidcal Affairs Dr. Douglas M. Hansell said. “Baxter plans to continue assessing data from the Starling registry to examine the role of hemodynamic monitoring across a variety of clinical settings and patient diagnoses.”